32462-30-9; OXFENICINE; 4-Hydroxy-L-phenylglycine; H-Phg(4-OH)-OH; L-4-Hydroxyphenylglycine; (S)-2-AMINO-2-(4-HYDROXYPHENYL)ACETIC ACID; (S)-Amino-(4-hydroxyphenyl)acetic acid; (2s)-Amino(4-Hydroxyphenyl)Acetic Acid; L-2-(p-Hydroxyphenyl)glycine; (2S)-2-amino-2-(4-hydroxyphenyl)acetic acid; (s)-(4-hydroxyphenyl)glycine; L-2-(4-Hydroxyphenyl)glycine; UK-25842; Oxfenicine (USAN/INN); (2S)-amino(4-hydroxyphenyl)ethanoic acid; 4-hydroxyphenylglycine, (s)-; L-P-HYDROXYPHENYGLYCINE; UK-25,842; 9YH0WH2Z02; DTXSID3046403; CHEBI:31755; DTXCID1026403; Oxfenicina; Oxfenicinum; (S)-4-hydroxyphenylglycine; CAS-32462-30-9; Oxfenicinum [INN-Latin]; p-Hydroxy-L-phenylglycine; Oxfenicina [INN-Spanish]; UNII-9YH0WH2Z02; L-(+)-A-4-HYDROXYPHENYLGLYCINE; Oxfenicine [USAN:INN:BAN]; MFCD00065932; NCGC00164509-01; EINECS 251-061-7; UK 25842; OXFENICINE [INN]; OXFENICINE [USAN]; (S)-alpha-Amino-4-hydroxybenzeneacetic acid; (S)-2-Amino-2-(4-hydroxyphenyl)essigsaeure; bmse000629; SCHEMBL122315; Benzeneacetic acid, .alpha.-amino-4-hydroxy-, (S)-; Benzeneacetic acid, alpha-amino-4-hydroxy-, (alphaS)-; CHEMBL1232077; 37784-25-1; 4-Hydroxy-L-(+)-2-phenylglycine; ACT05092; ZINC6667724; Tox21_112144; BDBM50403035; L-(+)-2-(4-Hydroxyphenyl)glycine; AKOS016842371; Tox21_112144_1; CS-W018812; DB04291; HY-W018026; NCGC00344518-01; AC-24628; DS-11081; H1389; 4-Hydroxy-L-phenylglycine, >=99.0% (NT); D05292; EN300-198950; A821286; Benzeneacetic acid, alpha-amino-4-hydroxy-, (S)-; (S)-(+)-2-Amino-2-(4-hydroxyphenyl)acetic Acid; AMOXICILLIN SODIUM IMPURITY I [EP IMPURITY]; J-018746; Q27095113; Z1255364887; (2S)-2-amino-2-(4-hydroxyphenyl)acetic acid;L-P-HYDROXYPHENYGLYCINE